In-Vivo Evaluation of the Antiplasmodial Effect of Amodiaquine and Amodiaquine-Promethazine Combination in Plasmodium berghei Infected Mice by Olalubi, OA et al.
Olalubi et al                                         Effect of Amodiaquine and Promethazine in Plasmodium berghei Infection 
 
Int J Health Res, June 2011; 4(2):   83 
International Journal of Health Research, June 2011; 4(2): 83-89  
© Poracom Academic Publishers.  All rights reserved. 
 
Available at http://www.ijhr.org 
 
 




In-Vivo Evaluation of the Antiplasmodial Effect of 
Amodiaquine and Amodiaquine-Promethazine Combination 
in Plasmodium berghei Infected Mice  
Abstract 
 
Purpose: Antihistamine H1 receptor antagonists like promethazine 
(PR) are capable of reversing resistance of Plasmodium  falciparum  
to some antimalarials drugs like amodiaquine (AQ). This work was 
carried out to evaluate the antiplasmodial activity of amodiaquine 
and amodiaquine-promethazine combination in Plasmodium berghei 
infected mice.  
Methods: Groups of mice (112) infected with chloroquine resistant 
Plasmodium berghei ANKA strain were treated with 10mg/kg 
amodiaquine alone for three days or 10mg/kg AQ combined with 
graded doses (10, 20, 30, 40, 50 mg/kg) of PR twice daily over 7 
days). Thin blood films were used to assess parasitemia for 60 days. 
Results: Therapeutic effect of AQ combined with graded doses of 
PR was dose-dependent with the combination of AQ and the highest 
concentration of PR (50mg/kg) having the shortest parasite clearance 
time (PCT) (1.28± 0.49) days and longest recrudescence time (RT) 
of (17.33±11.86 days) compare to AQ alone. The mean PCT was 
significantly reduced as doses of PR increased up to 50mg/kg 
(P<0.01). The survival rates (93.8% and 50%) in the group of 
animals receiving 50mg/kg of PR plus AQ and AQ alone, 
respectively were significantly different (P<0.01).   
Conclusion: Promethazine potentiates the therapeutic effects of 
amodiaquine against the chloroquine resistant P. berghei infection in 
male albino mice. 
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Introduction 
 
Amodiaquine is a mannich base congener of 
chloroquine with marginally better efficacy
 
[1]. 
As a result of widespread resistance, malaria 
therapy now consists of combination of two or 
more drugs that attack different biochemical 
processes in the Plasmodium species. 
Amodiaquine has been used in combination with 
artesunate or sulphadoxine –pyrimethamine with 
good result [2]. Though the combination of 
antimalarials in malaria therapy improved 
efficacy and reduced onset of resistance, it did 
not remove side effects like pruritus experienced 
with the administration of 4-aminoquinolines. 
This prompted the continuous search for a new 
class of resistance modulator drugs, which could 
be co-administered with amodiaquine, to 
effectively potentiate amodiaquine and reverse 
resistance without these side effects. In addition, 
poor sensitivity of P. falciparum to some 
antimalarial drugs have been reversed both in 
vitro and in vivo by the concomitant 
administration of antihistamine type 1 (H1) 
receptor notably chlorpheniramine and 
promethazine [3]. This resistance reversing 
capability of antihistamines remains to be fully 
elucidated. Nonetheless, resistance reversal 
provides yet another possible means to combating 
the malaria scourge. 
 
Chlorpheniramine and promethazine are 
commonly used in Nigeria for the purpose of 
reducing or preventing chloroquine –induced 
pruritus and are safe and well tolerated [4]. The 
ability of some non-antimalarial drugs to reverse 
chloroquine and amodiaquine resistance in 
Plasmodium falciparum is a well-established 
phenomenon and represents a useful alternative 
strategy to restore and prolong the clinical utility 
of both chloroquine and amodiaquine [5, 6, 7]. 
Clinical application of chlorpheniramine to 
potentiate the antimalarial activity of chloroquine 
has been demonstrated in patients
 
[7]. Both drugs 
are found to be safe and well-tolerated when 
administered in therapeutic doses
 
[8]. Detectable 
reversing activities in human plasma, after an oral 
ingestion of promethazine in bioassay, designed 
to evaluate the potentiating effect of 
promethazine on chloroquine in chloroquine 
resistant parasites, have been reported [9] .These 
attributes of promethazine make it a potential 
candidate compound that could be useful for the 
clinical application of the reversal phenomenon. 
However, detailed studies on efficacy and safety 
in animals and also other phases of drug 
development are essential before clinical 
application may be recommended. 
 
This study attempted to determine the efficacy 
and beneficial effect of amodiaquine, a 4-
aminoquinoline antimalarial agent in combination 
with promethazine, an antihistamine of high 
potency against chloroquine - resistant P. berghei 
infection in male albino mice. 
Materials and Methods 
Parasites and Experimental animals 
Chloroquine resistant Plasmodium berghei ANKA 
strain, obtained from Dr. Dennis Kyle of the 
Division of Experimental Therapeutics, Walter 
Reed Army Institute for Research, Washington 
DC  were maintained in mice by serial passage in 
the animal house of the Malaria Research 
Laboratories, Institute for Advanced Medical 
Research and Training, College of Medicine, 
University of Ibadan, Ibadan, Nigeria. 10-12 
week old in-bred male Swiss albino mice (24 – 
26 g) free from Eperythrozoon coccoides were 
used for the studies. The mice were kept in cages 
at room temperature, fed with standard mouse 
cubes (Ladokun Feeds Nigeria Limited) and 
provided with access to clean drinking water ad 
libitum.  
 
Inoculation of experimental animals 
 
Parasitized red blood cells used for inoculation 
were obtained by cardiac puncture from an 
infected donor mouse. The infected blood was 
collected in an anticoagulant and diluted to the 
desired parasite density in 0.9% normal saline 
(Kendall McGraw Laboratories inc. Irvine CA, 
USA). Each mouse was inoculated 
intraperitoneally with 1.0 x 10
6
 and 1.0x 10
7 
parasitized red blood cells of Plasmodium 
berghei strain suspension in 0.2 ml of inoculum. 
The day of inoculation was defined as day zero 
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(D0) and subsequent days as D1, D2, and D3 up 
to D60. 
 
Treatment of experimental animals 
  
One hundred and twelve (112) male mice were 
randomly allocated into seven groups of sixteen 
animals each. Six groups were treated with 
standard doses of amodiaquine alone and with 
amodiaquine combined with graded doses of 
promethazine. The last group received phosphate 
buffered saline (PBS) and served as control. 
Animals in the treatment group received 
amodiaquine alone, once daily for 3 days. Those 
treated with the combination drug received 
amodiaquine (10mg/kg) daily for 3 days 
combined with 10, 20, 30, 40, 50mg/kg 
promethazine orally every 12 hr (twice daily) for 
7 days. 
 
Course of infection of Plasmodium berghei 
ANKA strain in male albino mice (untreated 
control) 
 
Course of infection was monitored daily in each 
untreated mouse, starting from 72 hours (D3) 
after inoculation and until death.  Thin blood 
smears were prepared from blood obtained from 
tail snip in each animal, fixed with methanol and 
stained with Giemsa.  Red blood cells were 
classified into standard categories, based on 
differential stain uptake with Giemsa as (i) 
reticulocytes, which represent an immature, 
juvenile stage in the maturation of red blood cell 
between the normoblast and mature cell and (ii) 
mature red blood cells (erythrocytes), which 
stains pinkish under the microscope. The 
parasitized red blood cell (PRBCs) population 
therefore included both parasitized erythrocyte 
and parasitized reticulocytes. Number of 
parasitized reticulocytes was expressed as a 
percentage of total reticulocyte population.  
Mature RBC, both parasitized and non – 
parasitized were expressed as percentage of the 
total RBCs population of at least a 1000 RBCs 
counted and tabulated. Percentage parasitized 
cells were calculated and graphs were plotted 
from the raw data using the prism computer 
software. 
 
Determination of responses of infection to 
treatment 
  
Thin blood films were prepared every day till day 
9 and thereafter every other day till day 60 in all 
surviving animals. Giemsa stained thin blood 
films were examined under a high power 
microscope (Olympus, Japan) objective (x100) to 
enumerate parasite density. Parasite density was 
determined by counting the number of parasitized 
erythrocytes among at least 1000 red blood cells. 
  
Occurrence of clearance of parasites following 
treatment was determined in each animal as 
Parasite Clearance Time (PCT). The time taken 
for the parasites to reappear   in the animals 
during the 60 days of follow up was defined as 
the recrudescence time (RT). The number of 
animals surviving till 60days after inoculation in 
each group was also determined.  
Statistical analysis 
  
Student t-test was used to compare the mean 
parasite density, parasite clearance time, 
recrudescence time and survival rate. Values 




Course of infection of P. berghei (ANKA) in 
mice infected with 1.0 x 10
6
 and 1.0 x 
10
7
parasitized red blood cells without treatment 
was evaluated. Infection in this group of animals 
became noticeable 3 days (72 hours) after 
inoculation and followed an acute course. 
Infection in the animals inoculated with 1.0 x 10
6
 
inoculum size terminated in death occurring on 
day 10 (Table 1) Infections in the animals 
reached highest parasite density on day 6 with 
28.1% mean parasitaemia. This later reduced to 
17.0% on day 8 and 16.8% on D9. 
       
Similarly, infection in the animals inoculated 
with 1.0x 10
7
 also culminated into death at 
exactly day 7.  Infections in this group of animals 
also became noticeable 3 days after inoculation 
and followed an acute course. Infections reached 
highest  parasite  density  on  day  5  with  38.5%  
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Table 1: Course of infection of chloroquine-resistant Plasmodium berghei in untreated male albino mice 
 
Untreated           Mean Parasitaemia (%) 
Inoculum size D3 D4 D5 D6 D7 D8 D9 
1.0X106 0.3 7.0 12.8 28.1 17.4 17.0 16.8 
1.0X107 2.2 12.7 38.5 34.6 30.8   
 
Table 2: Response of chloroquine resistant Plasmodium berghei infection to graded dosages of  amodiaquine 
 
          Treatment                                  Response (Days) 
Treatment (mg/kg)     Parasite clearance Time (PCT) Recrudescence Time (RT) 
Amodiaquine (10mg/kg) 2.00 ± 0.00 5.75 ± 0.50 
Amodiaquine (20mg/kg) 2.20 ± 0.55 9.80 ± 0.84 
Amodiaquine (30mg/kg) 1.80 ± 0.45 11.25±1.89 
Amodiaquine (40mg/kg) 1.75 ± 0.50 13.20±2.49 
Amodiaquine (50mg/kg) 1.50 ± 0.71 24.25±6.90 
 
Table 3: Response of infection with 106 Chloroquine-resistant Plasmodium berghei to standard dose of 
amodiaquine alone, and amodiaquine plus graded doses of promethazine 
 
Treatment                                               Parasite Clearance time (PCT) Recrudescence time  (RT)       
Amodiaquine (30mg/kg) AQ 1.88 ± 0.44 5.25 ± 3.37 
AQ +Promethazine (10mg/kg) 2.00 ± 0.46 6.50 ± 4.55 
AQ+ Promethazine (20mg/kg) 2.10 ± 0.57 8.60 ± 6.31 
AQ+Promethazine (40mg/kg) 1.56 ± 0.53 9.44 ± 7.55 
AQ+ Promethazine (50mg/kg) 1.28 ± 0.49 17.33± 11.86 
 
mean parasitaemia, which later reduced to 30.8% 
on D7 before death (Table 1). In other words, for 
the 1 x 10
6
 inoculum size, mean parasitemia 
increased readily from the day 3, peaked on day 6 
and declined through to day 9. For the 1 x 10
7
 
inoculum size however, mean parasitemia 
increased from day 3, peaked on day 5 and 
declined from day 6 through day 7; the animals 
died on day 8. 
 
Generally, as the dose of amodiaquine increased, 
the parasite clearance time reduced while the 
recrudescence time increased (Table 2).  
 
Treatment with the combination of amodiaquine 
with selected doses of promethazine (10, 20, 30, 
40, 50 mg/kg) resulted in a significant difference 
in PCT and RT compared with animals treated 
with amodiaquine alone (p<0.01). As the dose of 
PR combined with AQ increased, PCT decreased 
while RT increased. Treatment with the 
combination of amodiaquine with 50mg/kg 
promethazine produced the shortest parasite 
clearance time of 1.28 ± 0.49 days and the 





None of the animals in the control group survived 
till day 60 (Table 4). The animals in the treatment 
groups (AQ alone and AQ +10, 20, 30, 40, 50 
mg/kg PR) were retreated (between Day 9 and 
10) 24 hours after noticing recrudescence 
parasites in the peripheral blood. Retreatment 
produced a longer curative effect and lengthened 
the survival period of the animals.  
 
Retreatment with standard dosage of AQ plus 20, 
30, 40 and 50 mg/kg concentration of 
promethazine produced survival rate between 75 
to 94 % of the animals. Blood samples from the 
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survived animals in each of the retreated groups 
failed to produce infection when sub-inoculated 
into other clean animals.  
 
Table 4: Effects of treatment with amodiaquine alone 
or amodiaquine in combination with graded dosages of 
promethazine on the survival of male albino mice 




No of rats 
alive on day 
60 (survival 
%)                   
No of rats 
alive on day 
60 (survival 

























Plasmodium berghei has proved to be very 
convenient for the detection of antimalarial 
activity and it is generally considered that the 
infection with this parasite in the mouse is a valid 
model for the primary screening of conventional 
drugs for eventual use against human malaria 
[10]. At initiation of infection (Day3), P. berghei 
infects erythrocytes and towards the peak of 
infection (Day 6), invades predominantly more 
reticulocytes. At this stage, the animal becomes 
anaemic, with remarkable increase in the rate of 
destruction of red blood cell, which eventually 
triggers the erythroid tissue to start producing 
more reticulocytes to compensate for the 
destroyed erythrocytes [14]. It has been 
confirmed in previous reports that the ratio of 
reticulocytes to mature RBCs at the peak of 
infections was approximately 4:1 in male albino 
mice inoculated with either 1 X 10
6
 parasitized 
red blood cells or with 1 X 10
7
 parasitized red 
blood cells [11, 12, 13]. In the absence of enough 
reticulocytes, parasites invaded the available 
mature red blood cells, resulting in rapid death of 
animals between day 7 and 8 post inoculation. 
However, when reticulocytes were available in 
large number, the course of infection of P.berghei 
ANKA in male albino mice may be altered [14]. 
Infection of large number of reticulocytes 
resulted in increasing the survival time of 
infected animals. Infected mice with a large 
number of infected reticulocytes died between 
day 7 and day 10 post inoculation. Similarly it 
was also reported that invasion of all erythrocyte 
population or a sub-population (for example 
reticulocytes) can have a profound effect on 
malarial pathogenesis [14].  
 
Recrudescence of infection documented on day 5 
in animal treated with 30 mg/kg amodiaquine is a 
confirmation of the R1 resistance nature of 
P.berghei ANKA to amodiaquine. General 
reappearance of parasitaemia (recrudescence) 
following treatment with the standard dosages of 
amodiaquine alone or amodiaquine in 
combination with graded dosages of 
promethazine against chloroquine resistant P. 
berghei infection appeared to be an evidence of 
cross-resistance. Infection in thin blood smears 
from animals treated with 30 mg/kg amodiaquine 
was found mostly in the reticulocytes. The 
relevance of this observation reveals that the 50 
% effective dose of amodiaquine within mature 
red blood cells inhibiting P. berghei is lower than 
that found in reticulocytes with decrease in 
amodiaquine sensitivity [15, 16]. 
 
Parasitaemia with lower grades of resistance 
disappear overtime from the peripheral blood 
below the level of microscopic detection but 
recur at a later time [16], this may be due to the 
longer retention time of amodiaquine acting 
synergistically with the host immune functions 
[17]. The potentiation appeared to be dose-
dependent. Length of reduction of infection to 
subtherapeutic level was also dependent on the 
dosage of promethazine administered. Infections 
in animals treated with standard dose of 
amodiaquine and the highest dose of 
promethazine (50 mg/kg) remain sub patent 
(delayed recrudescence) for a longer period 
compared with those treated with lower dosage 
and also with amodiaquine alone. Survival of 
infected mice was significantly prolonged when 
retreated after recrudescence with the 
combination of amodiaquine and promethazine 
with animals surviving till 60 days.  
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It is imperative from the course of infection 
studies (Control group) to stress the fact that the 
effect of maintaining infection by serial passaging 
of parasites in the laboratory did not alter the 
resistance of the P.berghei ANKA to 
amodiaquine. This finding is contrary to the 
findings of Peters [11, 16] which stipulated that, 
chloroquine resistant lines of P.berghei were 
initially unstable, in the absence of drug pressure 
and may revert rapidly to sensitivity in the course 
of a few blood passages in the absence of drug 
pressure [18].  Data obtained in the study also 
indicated an enhanced efficacy of amodiaquine 
when combined with selected dosages of 
promethazine compared to amodiaquine alone 
against chloroquine resistant P. berghei malaria 
infections. Reversal of amodiaquine resistance 
infection in mice was dose dependent. The 
mechanism of amodiaquine resistance and 
reversal of resistance is not yet fully understood. 
The significant recrudescence of patent infections 
experienced with the combinations of 
amodiaquine with varying concentrations of 
promethazine may be explained by the fact that 
promethazine at moderate concentration induces 
its own metabolism [19].These authors further 
stated that, this auto-inductive metabolism of 
promethazine might be acting on the cytochrome 
P450 enzymatic complex of the liver, which is 
involved in the metabolism of various drugs. 
 
Binding of drugs to plasma proteins especially 
albumin and acute phase proteins, is known to 
decrease antimalarial drugs efficacy [20]. Co-
administration of amodiaquine and promethazine 
had been shown to increase the degree of 
bioavailability of amodiaquine and its metabolites 
in the plasma [19, 20]. This increase could be 
explained by the presence of promethazine, 
which may competitively displace amodiaquine 
or its metabolites (desethylamodiaquine) from 
their original binding sites on plasma proteins 
[21]. The clinical and therapeutic implication of 
this increase is that the antiparasitic effect of the 
amodiaquine is increased. In addition, it is well 
established that the effect of amodiaquine is 
dependent on the unbound concentration of the 




The result of this study indicates that 
promethazine potentiates the therapeutic effects 
of amodiaquine against the chloroquine resistant 
P.berghei infection in the male albino mice. The 
reversal of amodiaquine resistance with the 
combination of amodiaquine and promethazine 
achieved in this study may play an important role 
in efforts to control drug resistant malaria at 
economically feasible costs. The potential value 
of combination of promethazine with 
amodiaquine in the management of amodiaquine 
resistant infections in man would ultimately 
depend on thorough pharmacokinetics and 
toxicological evaluation for they remain 
important prerequisites to clinical application of 
the reversal phenomenon. Also, additional studies 
on pharmacokinetic interactions of the two drugs 
are necessary to optimize dosage regimens of the 
combination in the management of amodiaquine 
resistant malaria [21]. 
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